TY - JOUR
T1 - C-type natriuretic peptide applied to the brain enhances exocrine pancreatic secretion through a vagal pathway
AU - Sabbatini, María E.
AU - Rodríguez, Myrian R.
AU - Corbo, Natalia S.
AU - Vatta, Marcelo S.
AU - Bianciotti, Liliana G.
N1 - Funding Information:
This work was supported by grants from Universidad de Buenos Aires (UBACYT B079 and B420).
PY - 2005/11/7
Y1 - 2005/11/7
N2 - C-type natriuretic peptide (CNP) is the major natriuretic peptide in the brain and its mRNA has been reported in the central nervous system, which supports local synthesis and its role as a neuromodulator. The aim of the present work was to study the effect of centrally applied CNP on pancreatic secretion. Rats were fitted with a lateral cerebroventricular cannula one-week before secretion studies. The central administration of CNP dose-dependently enhanced pancreatic fluid and protein output. CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy. Neither adrenergic antagonists nor the administration of (d-p-Cl-Phe6,Leu 17)-vasoactive intestinal peptide (VIP antagonist) or N ω Nitro-l arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor) affected CNP response. The effect induced by CNP was mimicked by 8-Br-cGMP but not by c-ANP-(4-23) amide (selective agonist of the natriuretic peptide receptor C). Furthermore, CNP interacted with cholecystokinin (CCK) and secretin in the brain to modify pancreatic secretion. Present findings show that centrally applied CNP enhanced pancreatic secretion through a vagal pathway and suggest that CNP response is mediated by the activation of natriuretic peptide guanylyl cyclase coupled receptors in the brain.
AB - C-type natriuretic peptide (CNP) is the major natriuretic peptide in the brain and its mRNA has been reported in the central nervous system, which supports local synthesis and its role as a neuromodulator. The aim of the present work was to study the effect of centrally applied CNP on pancreatic secretion. Rats were fitted with a lateral cerebroventricular cannula one-week before secretion studies. The central administration of CNP dose-dependently enhanced pancreatic fluid and protein output. CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy. Neither adrenergic antagonists nor the administration of (d-p-Cl-Phe6,Leu 17)-vasoactive intestinal peptide (VIP antagonist) or N ω Nitro-l arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor) affected CNP response. The effect induced by CNP was mimicked by 8-Br-cGMP but not by c-ANP-(4-23) amide (selective agonist of the natriuretic peptide receptor C). Furthermore, CNP interacted with cholecystokinin (CCK) and secretin in the brain to modify pancreatic secretion. Present findings show that centrally applied CNP enhanced pancreatic secretion through a vagal pathway and suggest that CNP response is mediated by the activation of natriuretic peptide guanylyl cyclase coupled receptors in the brain.
KW - C-type natriuretic peptide
KW - Central nervous system
KW - Exocrine pancreatic secretion
KW - Natriuretic peptide receptor A
KW - Natriuretic peptide receptor B
KW - c-ANP-(4-23) amide
KW - cGMP pathway
UR - http://www.scopus.com/inward/record.url?scp=27744594085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744594085&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2005.09.015
DO - 10.1016/j.ejphar.2005.09.015
M3 - Article
C2 - 16263110
AN - SCOPUS:27744594085
SN - 0014-2999
VL - 524
SP - 67
EP - 74
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -